Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04537156
Other study ID # HPV-PRO-009
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date September 5, 2020
Est. completion date December 31, 2027

Study information

Verified date June 2023
Source Xiamen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women aged 18-45 years old.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 9327
Est. completion date December 31, 2027
Est. primary completion date December 31, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Female aged between 18 and 45 years at the first vaccination; 2. Be able to understand and comply with the request of the protocol(e.g. biological specimen collection, diary card entry and attend regular follow-up), and sign written informed consent; 3. Women who agree to use effective contraception within 8 months after the first vaccination, or women who have undergone tubal ligation, benign subtotal hysterectomy, benign ovarian tumor removal, or postmenopausal women; 4. The number of sexual partners so far less than four; 5. Have intact cervix and have no history of physical or surgical treatment; 6. No previous history of sexually transmitted diseases (including syphilis, gonorrhea, chancroid, venereal lymphogranuloma, groin granuloma, etc.); 7. No previous history of abnormal cervical screening results or cervical intraepithelial neoplasia (CIN), and no abnormality in gynecological examination; 8. Sexual intercourse has occurred. Exclusion Criteria: 1. Participants with acute cervicitis and acute lower genital tract infection, or with obvious condyloma; 2. Participants during menstruation, or have vaginal medication, sexual behavior (including anal, vaginal or external genital contact, regardless of the sex of parterner) within two days (48 hours) before the visit, which may affect gynecological examinations and specimens collection. 3. Axillary temperature > 37.0?; 4. Participants who have positive urine pregnancy test, or are pregnant or breastfeeding; 5. Have used other investigational or unregistered products (drugs or vaccines) within 30 days before receiving the research vaccine or have participated in another clinical research in the past two years, or plan to use other research or unregistered products or participate in other research during the research period; 6. Long-term use (more than 14 continuous days) of immunosuppressors and other Immunoregulatory agents or systemic corticosteroids (Except intranasal steroid, the use of low dose topical, ophthalmic and inhaled steroid preparations will be permitted.) 6 months prior to vaccination. 7. Administration of immunoglobulin and/or blood products 3 months prior to vaccination or intending to use them during the study. 8. Administration of inactivated vaccine within 14 days before vaccination or live vaccine within 21 days; 9. Fever (Axillary temperature >38.0?) 3 days prior to vaccination or system administration of antibiotics or antiviral agents (Anti-flu agents include but are not limited to Tamiflu, Tamiflu, Symmetrel and Flumadine) 5 days prior to vaccination. 10. Have received other HPV vaccines or participated in clinical research related to HPV or cervical cancer previously; 11. Immunodeficiency disease, primary disease of important viscera, cancer and autoimmune disease (including systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy due to any condition, and other autoimmune diseases that investigators believe may influence the immune response). 12. History of severe allergy (e.g., anaphylaxis, generalized urticaria, dyspnea, angioedema, and other significant reaction) to any previous vaccines, or allergy to any of the components of investigational vaccine. 13. Asthma, which has been unstable for the past two years and requires emergency treatment, hospitalization, oral or intravenous corticosteroids; 14. Suffered from a serious medical illness; 15. Self-report past coagulation disorders or abnormal coagulation function; 16. Epilepsy, excluding febrile epilepsy under 2 years of age, alcoholic epilepsy 3 years prior to abstinence or simple epilepsy that did not require treatment in the past 3 years; 17. According to the judgement of investigator, various medical, psychological, social, vocational or other factors that are not suitable for participating in the clinical trial.

Study Design


Intervention

Biological:
Nonavalent HPV vaccine
Nonavalent HPV vaccine (270µg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Bivalent HPV vaccine
Bivalent HPV vaccine (60µg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

Locations

Country Name City State
China Sichuan Provincial Centre for Disease Control and Prevention Chengdu Sichuan
China Jiangsu Provincial Centre for Disease Control and Prevention Nanjing Jiangsu

Sponsors (3)

Lead Sponsor Collaborator
Xiamen University Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen Innovax Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of CIN2 + and/or VIN2 + and/or VaIN2 + lesions related to HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68 (Combined analysis of the high risk types) To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Other Incidence of CIN1 + and/or VIN1 + and/or VaIN1 + lesions related to HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68 (Combined analysis of the high risk types) To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Other Incidence of Persistent infection of HPV35, 39,51,56,59 and 68 (total infection and over 6 months and over 12 months) (Independent analysis of each type) To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Primary Non-inferiority of anti-HPV 16 and 18 seroconversion rates and geometric mean concentrations at Months 7 (type specific neutralizing antibody) in the PPS-I set Detect the level of anti-HPV 16 and 18 specific neutralizing antibodies at one month after the third dose to determine whether nine-valent HPV vaccine is non-inferior to the control bivalent HPV vaccine Specific neutralizing antibodies at 7 months after first dose
Primary Persistent infection of HPV31, 33, 45, 52 and 58 (over 12 months) (Combined analysis of the 5 types) in the mITT-PI set To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Primary Incidence of CIN2 + and/or VIN2 + and/or VaIN2 + lesions related to HPV 31, 33, 45, 52 or 58 (Combined analysis of the 5 types) in the mITT-E when the first two endpoints are satisfied To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Secondary Efficacy1: Incidence of CIN2 + and/or VIN2 + and/or VaIN2 + lesions related to HPV 31, 33, 45, 52 or 58(Combined analysis of the 5 types) and genital warts related to HPV 6, 11 (Combined analysis of each type) To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Secondary Efficacy2: Incidence of CIN1 + and/or VIN1 + and/or VaIN1 + lesions related to HPV 31, 33, 45, 52 or 58(Combined analysis of the 5 types) and genital warts related to HPV 6, 11 (Combined analysis of each type) To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Secondary Efficacy3: Incidence of Persistent infection of HPV31, 33, 45, 52 and 58 (transient infection and over 6 months) (Combined analysis of the 5 types) To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Secondary Efficacy4: Incidence of CIN1 + and/or VIN1 + and/or VaIN1 + lesions related to HPV 31, 33, 45, 52 or 58(Combined analysis of the 5 types) To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Secondary Efficacy5: Incidence of Persistent infection of HPV31, 33, 45, 52 and 58 (over 6 months) and/or incidence of CIN1 + and/or VIN1 + and/or VaIN1 + lesions related to HPV 31, 33, 45, 52 or 58(Combined analysis of the 5 types) To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Secondary Efficacy6: Incidence of genital warts related to HPV 6, 11 To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Secondary Efficacy7: Incidence of Persistent infection of HPV31, 33, 45, 52, 58, 6 and 11 (transient infection and over 6 months and over 12 months) (Combined analysis of the 7 types) To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Secondary Efficacy8: Incidence of Persistent infection of HPV31, 33, 45, 52, 58, 6 and 11 (over 6 months and over 12 months) (Independent analysis of each type) To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine Cumulative incidence of this endpoint events in 78 months after the first dose
Secondary Immunogenicity1: Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 7 Analysis the seroconversion and geometric mean concertration of the type specific antibodies of the 7 types. Month 7 after first vaccination
Secondary Immunogenicity2: Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 18 and 30 Analysis the seroconversion and geometric mean concertration of the type specific antibodies of the 7 types. Month 18 and 30 after first vaccination
Secondary Immunogenicity3: Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 42, 54, 66 and 78 Analysis the seroconversion and geometric mean concertration of the type specific antibodies of the 7 types. Month 42, 54, 66 and 78 after first vaccination
Secondary Safety1: Local and systematic adverse events/reactions occurred within 7 days after each vaccination safety analysis During the 7-day (Day 0-6) period following each vaccination
Secondary Safety2: Adverse events/reactions occurred within 30 days after each vaccination safety analysis Within 30 days (Day 0-30) after any vaccination
Secondary Safety3: Serious adverse events occurred throughout the study safety analysis. To evaluate number of SAEs compared with the control vaccine. Up to 78 month
Secondary Safety4: Pregnancy and pregnancy outcome safety analysis. To evaluate number of births and terminations compared with the control vaccine. Up to 78 month
Secondary Safety5: Emerging chronic diseases safety analysis.To evaluate number of emerging chronic diseases compared with the control vaccine. Up to 78 month
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A
Completed NCT02420665 - Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia Early Phase 1